Akseli Hemminki is the founder of TILT Biotherapeutics. TILT Biotherapeutics has raised $78M in total funding. Latest round: Series B.
Akseli Hemminki is the Co-founder and Chief Executive Officer of TILT Biotherapeutics, a clinical-stage biotechnology company developing oncolytic immunotherapies for solid tumors. He also serves as a Professor of Oncology, contributing his academic expertise to the company's virus-based cancer therapy pipeline. Hemminki has guided TILT through several funding rounds, including a recent USD 25.6 million Series B in May 2025.
Full founder directory · Investor directory · Company funding database · Fundraising library